Generic Times Product News

Pharmacy Times
Volume 0

Morphine Sulfate Concentrated Oral Solution InveAmp Ampoules

Marketed by:ETHEX Corp (St. Louis, Mo)

Compared to:Roxanol (Xanodyne) and MSIR Oral SolutionConcentrate (Purdue Frederick)

Indication:ETHEX recently introduced 2 new dosages—10mg/0.5 mL and 5 mg/0.25 mL—of Morphine Sulfateimmediate-release Concentrated Oral SolutionInveAmp Ampoules. The product is indicated for therelief of severe acute and chronic pain. EachInveAmp ampoule is individually wrapped in a foilpouch for ease of identification. Also, each foilpouch is bar-coded to help improve dispensingaccuracy and reverse-numbered to enhance inventorycontrol.

Dosage Form:Ampoules: 5 mg/0.25 mL; 10 mg/0.5 mL;20 mg/1 mL

For More

Sertraline Hydrochloride Tablets, 25, 50, and 100 mg

Marketed by:RoxaneLaboratories Inc (Columbus, Ohio), a subsidiary ofBoehringer Ingelheim Corp

Compared to:Zoloft Tablets (Pfizer Inc)

Indication:February 6, 2007—Roxane Laboratories announcedthe launch of Sertraline Hydrochloride Tablets, 25,50, and 100 mg. Sertraline hydrochloride is a selectiveserotonin reuptake inhibitor for oral administration.These tablets are indicated for the treatmentof major depressive disorder in adults.

Dosage Form:Tablets: 25, 50, and 100 mg

For More Information:www.roxane.com800-962-8364

Simvastatin Tablets USP, 5, 10, 20, 40, and 80 mg

Marketed by:Perrigo Co(Allegan, Mich)

Compared to:Zocor Tablets (Merck & Co Inc)

Indication:December 19, 2006—The Perrigo Co announcedthat it received final approval from the FDA to marketSimvastatin Tablets USP, 5, 10, 20, 40, and 80mg. Perrigo's partner, Bentley Pharmaceuticals Inc,is manufacturing the product in Zaragoza, Spain.These tablets are a lipid-lowering agent and haveseveral cardiovascular indications: for the treatmentof patients with coronary heart disease (CHD)or at high risk of CHD or for reductions in risk ofCHD mortality and cardiovascular events; patientswith hypercholesterolemia requiring modificationsof lipid profiles; and adolescent patients with heterozygousfamilial hypercholesterolemia.

Dosage Form:Tablets: 5, 10, 20, 40, and 80 mg

For More

Sodium Sulfacetamide Lotion, 10%

Marketed by:Prasco Laboratories(Cincinnati, Ohio)

Compared to:Klaron (sanofi-aventis)

Indication:January 16, 2007—PrascoLaboratories began shippingSodium Sulfacetamide Lotion 10%,the authorized generic of sanofiaventis'Klaron. Sodium Sulfacetamide Lotion 10%is AB-rated to Klaron and is indicated in the topicalcontrol of acne vulgaris. Each milliliter of SodiumSulfacetamide Lotion 10% contains 100 mg of sodiumsulfacetamide in a vehicle consisting of purifiedwater; propylene glycol; lauramide DEA anddiethanolamine; polyethylene glycol 400, monolaurate;hydroxyethyl cellulose; sodium chloride; sodiummetabisulfite; methylparaben; xanthan gum;ethylenediaminetetraacetic acid; and simethicone.

Dosage Form:118-mL bottle

For More

Related Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs
© 2024 MJH Life Sciences

All rights reserved.